

Project Name: HepCULater – Detect and Protect (an amendment to existing Joint Working)
Organisations: Midlands Partnership NHS Foundation Trust
Start Date: 08/2025

Summary:

HepCULater has successfully delivered impactful programmes addressing health inequalities. With NHS England's renewed focus on detecting all forms of viral hepatitis, the programme will now be extended to target hepatitis B and D, which are often misunderstood and underdiagnosed.

Objectives: The extension aims to improve prevention, case finding, and treatment of hepatitis B and D, supporting WHO and NHS England goals. It will target general practice and the public, with resources available to a wide range of stakeholders.

Benefits:

Patients: *Earlier diagnosis and access to treatment. *Reduced disease progression and complications. *Prevention of onward transmission. *Increased awareness and reduced stigma. *Access to educational materials and support pathways.

Organisation/NHS: *Supports national elimination goals for hepatitis B, D, and C. *Strengthens workforce capabilities and confidence. *Enhances data use and service-level interventions. *Promotes innovative care pathways and public health protection. *Builds legacy infrastructure and networks for sustained impact.

Gilead: *Supports public health goals aligned with corporate mission. *Enhances understanding of early testing and care pathways. *Strengthens relationships with NHS and healthcare stakeholders. *Demonstrates commitment to ethical joint working under ABPI Code.

Contact:

Matt Milner , Associate Director, Patient Access To Care - matt.milner@gilead.com